Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert commentary synthesizing Phase II and III clinical trial data without systematic review methodology.
PubMed 28617060 · doi:10.1080/17512433.2017.1341308
What was done
This narrative review summarizes the composition, mechanisms of action, and Phase II and III clinical trial findings on efficacy, safety, and tolerability for a low-dose, smaller-framed levonorgestrel-releasing intrauterine system (LNG-IUS 12) designed for up to five years of use.
What was found
The abstract reports that LNG-IUS 12 provides 5-year contraceptive efficacy with a first-year pregnancy rate under 1%, comparable to LNG-IUS 20 products. It is noted to have lower amenorrhea rates than higher-dose devices while sharing the smaller frame and narrower insertion tube of LNG-IUS 8. Detailed numeric outcomes, effect sizes, and adverse event frequencies are not reported in the abstract.
Why it matters
LNG-IUS 12 provides an alternative long-acting reversible contraceptive option that combines a smaller frame and narrower insertion profile with five-year efficacy and reduced rates of amenorrhea relative to higher-dose systems.
Limits
As a narrative review, no primary data, participant sample sizes, systematic search criteria, or detailed quantitative comparative statistics are reported in the abstract.
Cited by
- supports The Kyleena intrauterine device is physically smaller in size than the Mirena intrauterine device.